Algorae Pharmaceuticals (ASX:1AI) has taken another step in building a diversified commercial medicines platform, finalising a new licensing and supply agreement that broadens its reach beyond oncology into cardiovascular and metabolic disease markets.
The AI-enabled pharmaceutical company has executed a definitive licence and supply agreement with India-based Cadila Pharmaceuticals, paving the way for the launch of two generic medicines in Australia and New Zealand (ANZ). The agreement follows a binding term sheet announced in October 2025 and marks a further acceleration of Algorae’s commercialisation strategy.
Under the arrangement, Cadila will be responsible for developing and manufacturing the products, leveraging its vertically integrated operations and global manufacturing capabilities. Algorae, through its wholly owned subsidiary AlgoraeRx, will act as the Therapeutic Goods Administration sponsor, managing regulatory submissions and leading market access and commercialisation across the ANZ region.
The Cadila partnership complements Algorae’s existing portfolio of commercial agreements. These include an exclusive licensing deal with Sakar Healthcare to introduce five generic oncology medicines in ANZ, as well as a recent distribution agreement with Dr. Reddy’s Laboratories to supply Capecitabine 500 mg tablets into the Australian market. The first shipment under that agreement was received in January 2026, signalling early execution momentum.
Collectively, these partnerships position Algorae as a multi-therapy commercial operator spanning oncology, cardiovascular and metabolic disorders. The company now has a diversified product base targeting hospitals, pharmacies and institutional customers, reducing reliance on any single therapeutic area while strengthening revenue potential.
Algorae said it will now commence planning and documentation for TGA registration of the new products. The company has indicated that it will keep shareholders informed of submission timelines, anticipated launch windows, and expected revenue contributions as the program progresses.